Trial Profile
A Phase I Trial of Bizelesin (NSC 615291) Using a Single Bolus Infusion Given Every Twenty-eight (28) Days in Patients With Advanced Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Jun 2014
Price :
$35
*
At a glance
- Drugs Bizelesin (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 09 Jun 2014 New trial record